非酒精性脂肪性肝炎生物標記市場規模、佔有率和成長分析（按類型、最終用戶和地區）- 產業預測，2025-2032 年

2023 年全球非酒精性脂肪性肝炎生物標記市場規模價值為 10.1 億美元，預計將從 2024 年的 13 億美元成長到 2032 年的 97.8 億美元，預測期內（2025-2032 年）的複合年成長率為 28.7%。

全球非酒精性脂肪性肝炎 (NASH) 生物標記市場預計將出現顯著成長，這得益於與肥胖和代謝紊亂相關的慢性肝病 NASH 的盛行率不斷上升。發病率的快速增加凸顯了對可靠生物標記的需求，以便早期診斷、監測病情進展和評估治療反應。生物標記對於識別風險群、區分 NASH 與其他肝病以及評估嚴重程度至關重要。新型非侵入性診斷工具的研究和開發不斷進步，進一步增強了這個市場。隨著對有效診斷和監控解決方案的需求不斷增加，市場相關人員有充足的機會創新並推出滿足 NASH 管理關鍵需求的基於尖端生物標記的產品。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步

非酒精性脂肪性肝炎生物標記市場規模（按類型和複合年成長率）（2025-2032）

• 市場概況
• 肝纖維化生物標記
• 血清生物標記
• 氧化壓力生物標記
• 細胞凋亡生物標記
• 其他

非酒精性脂肪性肝炎生物標記市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 研究和學術機構
• 診斷中心
• 製藥和 CRO
• 醫院和診所
• 其他

非酒精性脂肪性肝炎生物標記市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Genfit SA（France）
• Gilead Sciences, Inc.（United States）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• Siemens Healthineers AG（Germany）
• Bio-Rad Laboratories, Inc.（United States）
• Abbott Laboratories（United States）
• Prometheus Laboratories Inc.（United States）
• NGM Biopharmaceuticals, Inc.（United States）
• Metabolon, Inc.（United States）
• Perspectum Ltd（United Kingdom）
• Precision Medicine Group, Inc.（United States）
• Grifols, SA（Spain）
• Hologic, Inc.（United States）
• Quest Diagnostics Incorporated（United States）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Biopredictive（France）

結論和建議

Global Non-alcoholic Steatohepatitis Biomarkers Market size was valued at USD 1.01 billion in 2023 and is poised to grow from USD 1.3 billion in 2024 to USD 9.78 billion by 2032, growing at a CAGR of 28.7% during the forecast period (2025-2032).

The Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is poised for substantial growth, fueled by the rising prevalence of NASH, a chronic liver condition linked to obesity and metabolic disorders. This surge in incidence underscores the need for reliable biomarkers for early diagnosis, monitoring disease progression, and evaluating therapeutic responses. Biomarkers are essential for identifying at-risk individuals, distinguishing NASH from other liver diseases, and assessing severity. The market is further bolstered by advancements in research and the development of novel, non-invasive diagnostic tools. As the demand for effective diagnostic and monitoring solutions grows, market players have ample opportunities to innovate and introduce cutting-edge biomarker-based products, fulfilling the critical needs in NASH management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Alcoholic Steatohepatitis Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Alcoholic Steatohepatitis Biomarkers Market Segmental Analysis

Global Non-alcoholic SteatohepatitisbiomarkersMarket is segmented by Type, End User and region. Based on Type, the market is segmented into Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers and Others. Based on End User, the market is segmented into Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Alcoholic Steatohepatitis Biomarkers Market

A significant driver fueling the global Non-Alcoholic Steatohepatitis (NASH) biomarkers market is the alarming rise in NASH cases globally. This liver condition, characterized by excess fat buildup that leads to inflammation and liver damage, is increasingly prevalent due to factors such as obesity, sedentary lifestyles, and poor dietary choices. Consequently, there is a heightened demand for reliable biomarkers that can facilitate early diagnosis, monitor the progression of the disease, and evaluate treatment efficacy. The escalating awareness surrounding NASH and the necessity for improved diagnostic methods further amplify the need for effective biomarkers in this growing market.

Restraints in the Global Non-Alcoholic Steatohepatitis Biomarkers Market

A notable challenge facing the Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers market is the absence of standardized biomarkers coupled with regulatory hurdles. The intricate processes involved in developing and validating biomarkers for NASH diagnosis and monitoring create significant barriers. The lack of consensus regarding the selection and application of these biomarkers limits their adoption across the industry. Moreover, regulatory bodies enforce strict validation requirements that can be both time-consuming and costly for developers. These complexities hinder the commercialization and acceptance of NASH biomarkers in clinical settings. To overcome these challenges, further research, standardization, and expert regulatory guidance are essential for maximizing the efficacy of NASH biomarkers and enhancing patient care.

Market Trends of the Global Non-Alcoholic Steatohepatitis Biomarkers Market

The global Non-Alcoholic Steatohepatitis (NASH) biomarkers market is witnessing a significant trend towards the adoption of non-invasive diagnostic techniques, reflecting the growing emphasis on patient-centric healthcare. NASH, characterized by complex liver pathology, necessitates early and accurate diagnosis for optimal management. In this landscape, non-invasive biomarkers, including advanced blood-based assays and imaging methods, are emerging as preferred alternatives to traditional liver biopsies, offering enhanced patient comfort, cost-efficiency, and accessibility. This shift not only promises to improve patient outcomes through timely intervention but also facilitates smoother clinical trial processes. As the demand for reliable and convenient diagnostics increases, this trend is poised to accelerate the growth of the global NASH biomarkers market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by Type & CAGR (2025-2032)

• Market Overview
• Hepatic Fibrosis Biomarkers
• Serum Biomarkers
• Oxidative Stress Biomarkers
• Apoptosis Biomarkers
• Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by End User & CAGR (2025-2032)

• Market Overview
• Research Institutes and Academics
• Diagnostic Centres
• Pharmaceutical Companies and CROs
• Hospitals and Clinics
• Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size & CAGR (2025-2032)

• North America (Type, End User)
  • US
  • Canada
• Europe (Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Genfit SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prometheus Laboratories Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NGM Biopharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolon, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perspectum Ltd (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision Medicine Group, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biopredictive (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations